Does the media refer more to SOPH or SEPN?

In the previous week, SOPHiA GENETICS and SOPHiA GENETICS both had 3 articles in the media. SOPHiA GENETICS's average media sentiment score of 0.91 beat Septerna's score of 0.55 indicating that SOPHiA GENETICS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SOPHiA GENETICS 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, COAG or SOPH?

Hemab Therapeutics has higher earnings, but lower revenue than SOPHiA GENETICS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A SOPHiA GENETICS $81.18M 4.03 -$79M -$0.52 N/A

Does the media favor COAG or SOPH?

In the previous week, Hemab Therapeutics had 2 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 5 mentions for Hemab Therapeutics and 3 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 0.91 beat Hemab Therapeutics' score of 0.61 indicating that SOPHiA GENETICS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SOPHiA GENETICS 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SOPH or HROW more profitable?

Harrow has a net margin of -5.57% compared to SOPHiA GENETICS's net margin of -44.48%. Harrow's return on equity of 19.59% beat SOPHiA GENETICS's return on equity. Company Net Margins Return on Equity Return on Assets SOPHiA GENETICS -44.48% -62.74% -21.85% Harrow -5.57% 19.59% 2.26%

Does the media prefer SOPH or HROW?

In the previous week, Harrow had 1 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 4 mentions for Harrow and 3 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 0.91 beat Harrow's score of 0.81 indicating that SOPHiA GENETICS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SOPHiA GENETICS 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SOPH or WVE?

In the previous week, WAVE Life Sciences had 2 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 5 mentions for WAVE Life Sciences and 3 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 0.91 beat WAVE Life Sciences' score of 0.32 indicating that SOPHiA GENETICS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SOPHiA GENETICS 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

SOPHiA GENETICS (SOPH) Competitors

$4.78 -0.16 (-3.24%)

Closing price 04:00 PM Eastern

Extended Trading

$4.78 +0.00 (+0.10%)

As of 05:46 PM Eastern

Compare

SOPH vs. SEPN, AVBP, COAG, HROW, and WVE

Should you buy SOPHiA GENETICS stock or one of its competitors? MarketBeat compares SOPHiA GENETICS with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SOPHiA GENETICS include Septerna (SEPN), ArriVent BioPharma (AVBP), Hemab Therapeutics (COAG), Harrow (HROW), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.

How does SOPHiA GENETICS compare to Septerna?

SOPHiA GENETICS (NASDAQ:SOPH) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

SOPHiA GENETICS has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Septerna has a beta of 2.39, indicating that its stock price is 139% more volatile than the broader market.

SOPHiA GENETICS has a net margin of -44.48% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%
Septerna	-49.88%	-12.72%	-8.87%

SOPHiA GENETICS currently has a consensus target price of $7.50, indicating a potential upside of 56.90%. Septerna has a consensus target price of $43.13, indicating a potential upside of 41.16%. Given SOPHiA GENETICS's higher probable upside, analysts clearly believe SOPHiA GENETICS is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, SOPHiA GENETICS and SOPHiA GENETICS both had 3 articles in the media. SOPHiA GENETICS's average media sentiment score of 0.91 beat Septerna's score of 0.55 indicating that SOPHiA GENETICS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SOPHiA GENETICS	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Septerna has lower revenue, but higher earnings than SOPHiA GENETICS. Septerna is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$81.18M	4.03	-$79M	-$0.52	N/A
Septerna	$45.95M	29.97	-$48.88M	-$0.81	N/A

31.6% of SOPHiA GENETICS shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by insiders. Comparatively, 4.3% of Septerna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

SOPHiA GENETICS and Septerna tied by winning 8 of the 16 factors compared between the two stocks.

How does SOPHiA GENETICS compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

ArriVent BioPharma has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ArriVent BioPharma presently has a consensus target price of $43.38, suggesting a potential upside of 45.65%. SOPHiA GENETICS has a consensus target price of $7.50, suggesting a potential upside of 56.90%. Given SOPHiA GENETICS's higher probable upside, analysts clearly believe SOPHiA GENETICS is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

ArriVent BioPharma has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. ArriVent BioPharma's return on equity of -48.98% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%

SOPHiA GENETICS has higher revenue and earnings than ArriVent BioPharma. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
SOPHiA GENETICS	$81.18M	4.03	-$79M	-$0.52	N/A

In the previous week, SOPHiA GENETICS had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 3 mentions for SOPHiA GENETICS and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.87 beat SOPHiA GENETICS's score of 0.91 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
ArriVent BioPharma	Very Positive
SOPHiA GENETICS	Positive

Summary

ArriVent BioPharma beats SOPHiA GENETICS on 9 of the 16 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Hemab Therapeutics currently has a consensus price target of $41.75, suggesting a potential upside of 59.53%. SOPHiA GENETICS has a consensus price target of $7.50, suggesting a potential upside of 56.90%. Given Hemab Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Hemab Therapeutics is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Hemab Therapeutics has higher earnings, but lower revenue than SOPHiA GENETICS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
SOPHiA GENETICS	$81.18M	4.03	-$79M	-$0.52	N/A

Hemab Therapeutics has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. Hemab Therapeutics' return on equity of 0.00% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%

31.6% of SOPHiA GENETICS shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Hemab Therapeutics had 2 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 5 mentions for Hemab Therapeutics and 3 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 0.91 beat Hemab Therapeutics' score of 0.61 indicating that SOPHiA GENETICS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SOPHiA GENETICS	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Hemab Therapeutics beats SOPHiA GENETICS on 7 of the 11 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Harrow?

SOPHiA GENETICS (NASDAQ:SOPH) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

SOPHiA GENETICS has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Harrow has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market.

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Comparatively, 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Harrow has a net margin of -5.57% compared to SOPHiA GENETICS's net margin of -44.48%. Harrow's return on equity of 19.59% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%
Harrow	-5.57%	19.59%	2.26%

SOPHiA GENETICS currently has a consensus price target of $7.50, indicating a potential upside of 56.90%. Harrow has a consensus price target of $69.43, indicating a potential upside of 108.37%. Given Harrow's stronger consensus rating and higher possible upside, analysts plainly believe Harrow is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Harrow had 1 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 4 mentions for Harrow and 3 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 0.91 beat Harrow's score of 0.81 indicating that SOPHiA GENETICS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SOPHiA GENETICS	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harrow has higher revenue and earnings than SOPHiA GENETICS. Harrow is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$81.18M	4.03	-$79M	-$0.52	N/A
Harrow	$272.30M	4.56	-$5.14M	-$0.41	N/A

Summary

Harrow beats SOPHiA GENETICS on 13 of the 16 factors compared between the two stocks.

How does SOPHiA GENETICS compare to WAVE Life Sciences?

SOPHiA GENETICS (NASDAQ:SOPH) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

In the previous week, WAVE Life Sciences had 2 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 5 mentions for WAVE Life Sciences and 3 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 0.91 beat WAVE Life Sciences' score of 0.32 indicating that SOPHiA GENETICS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SOPHiA GENETICS	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

SOPHiA GENETICS has higher revenue and earnings than WAVE Life Sciences. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$81.18M	4.03	-$79M	-$0.52	N/A
WAVE Life Sciences	$42.73M	25.94	-$204.38M	-$1.06	N/A

SOPHiA GENETICS has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, indicating that its stock price is 233% less volatile than the broader market.

SOPHiA GENETICS has a net margin of -44.48% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

SOPHiA GENETICS currently has a consensus price target of $7.50, suggesting a potential upside of 56.90%. WAVE Life Sciences has a consensus price target of $27.25, suggesting a potential upside of 373.09%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Summary

WAVE Life Sciences beats SOPHiA GENETICS on 9 of the 16 factors compared between the two stocks.

Get SOPHiA GENETICS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SOPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SOPH vs. The Competition

Export

Metric	SOPHiA GENETICS	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$327.36M	$1.55B	$6.25B	$12.42B
Dividend Yield	N/A	N/A	2.69%	5.29%
P/E Ratio	-9.19	77.62	22.29	24.19
Price / Sales	4.03	23.43	581.44	138.36
Price / Cash	N/A	23.15	42.31	57.88
Price / Book	6.93	4.77	9.84	6.72
Net Income	-$79M	-$54.76M	$3.57B	$337.19M
7 Day Performance	-5.91%	-0.78%	-1.17%	0.48%
1 Month Performance	-10.15%	4.20%	3.84%	5.06%
1 Year Performance	57.76%	-3.40%	27.39%	34.27%

SOPHiA GENETICS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SOPH SOPHiA GENETICS	2.3684 of 5 stars	$4.78 -3.2%	$7.50 +56.9%	+69.8%	$327.36M	$81.18M	N/A	520
SEPN Septerna	2.3438 of 5 stars	$30.65 +8.1%	$43.13 +40.7%	+201.5%	$1.28B	$45.95M	N/A	N/A
AVBP ArriVent BioPharma	2.5133 of 5 stars	$27.94 +4.5%	$43.13 +54.3%	+36.0%	$1.24B	N/A	N/A	40
COAG Hemab Therapeutics	4.8106 of 5 stars	$27.84 +7.5%	$41.75 +50.0%	N/A	$1.23B	N/A	N/A	72	News Coverage Short Interest Increase Gap Down
HROW Harrow	4.4484 of 5 stars	$34.17 +3.5%	$69.43 +103.2%	+9.6%	$1.23B	$268.68M	N/A	180	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SOPH) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SOPHiA GENETICS (SOPH) Competitors

SOPH vs. SEPN, AVBP, COAG, HROW, and WVE

How does SOPHiA GENETICS compare to Septerna?

Summary

How does SOPHiA GENETICS compare to ArriVent BioPharma?

Summary

How does SOPHiA GENETICS compare to Hemab Therapeutics?

Summary

How does SOPHiA GENETICS compare to Harrow?

Summary

How does SOPHiA GENETICS compare to WAVE Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOPH vs. The Competition

SOPHiA GENETICS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SOPHiA GENETICS (SOPH) Competitors

SOPH vs. SEPN, AVBP, COAG, HROW, and WVE

How does SOPHiA GENETICS compare to Septerna?

Which has more volatility and risk, SOPH or SEPN?

Is SOPH or SEPN more profitable?

Do analysts prefer SOPH or SEPN?

Does the media refer more to SOPH or SEPN?

Which has preferable earnings & valuation, SOPH or SEPN?

Do institutionals and insiders have more ownership in SOPH or SEPN?

Summary

How does SOPHiA GENETICS compare to ArriVent BioPharma?

Which has more volatility and risk, AVBP or SOPH?

Do insiders & institutionals have more ownership in AVBP or SOPH?

Do analysts recommend AVBP or SOPH?

Is AVBP or SOPH more profitable?

Which has higher valuation & earnings, AVBP or SOPH?

Does the media favor AVBP or SOPH?

Summary

How does SOPHiA GENETICS compare to Hemab Therapeutics?

Do analysts recommend COAG or SOPH?

Which has preferable earnings and valuation, COAG or SOPH?

Is COAG or SOPH more profitable?

Do institutionals and insiders have more ownership in COAG or SOPH?

Does the media favor COAG or SOPH?

Summary

How does SOPHiA GENETICS compare to Harrow?

Which has more risk and volatility, SOPH or HROW?

Do institutionals & insiders believe in SOPH or HROW?

Is SOPH or HROW more profitable?

Do analysts recommend SOPH or HROW?

Does the media prefer SOPH or HROW?

Which has higher earnings and valuation, SOPH or HROW?

Summary

How does SOPHiA GENETICS compare to WAVE Life Sciences?

Does the media refer more to SOPH or WVE?

Do insiders & institutionals have more ownership in SOPH or WVE?

Which has preferable earnings and valuation, SOPH or WVE?

Which has more risk and volatility, SOPH or WVE?

Is SOPH or WVE more profitable?

Do analysts prefer SOPH or WVE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOPH vs. The Competition

SOPHiA GENETICS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools